Elacestrant for treating oestrogen receptor-positive, HER2-negative advanced breast cancer with an ESR1 mutation after at least 1 endocrine treatment [ID6225] Draft guidance Technology appraisal ...

We use the best available evidence to develop recommendations that guide decisions in health, public health and social care.

Suggested remit: To appraise the clinical and cost effectiveness of vutrisiran within its marketing authorisation for treating transthyretin amyloidosis with cardiomyopathy ...

This licence allows individuals, commercial organisations and non-commercial organisations to reuse NICE content free of charge in their publications, products and systems. It applies to requests to ...

A list of downloadable documents created during development.

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

NICE Pathways offer an easy-to-use, intuitive way of accessing our clinical, public health and social care information. They include up to date NICE guidance, quality standards and related information ...

For further information on the guideline development process, please see how we develop NICE guidelines ...

Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...

A list of downloadable documents created during development.